What is Cara Therapeutics' stock symbol?
Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."
Where is Cara Therapeutics' stock going? Where will Cara Therapeutics' stock price be in 2017?
9 brokers have issued 12 month price targets for Cara Therapeutics' stock. Their predictions range from $17.00 to $32.00. On average, they expect Cara Therapeutics' stock price to reach $23.90 in the next twelve months.
When will Cara Therapeutics announce their earnings?
Cara Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March, 8th 2017.
What are analysts saying about Cara Therapeutics stock?
Here are some recent quotes from research analysts about Cara Therapeutics stock:
According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (1/3/2017)
Needham & Company LLC analysts commented, "Cara provided a quarterly corporate update yesterday. A revised IV CR845 Phase 2/3 postsurgical pain trial was initiated in Jun 2016. We believe an interim analysis may take place in 1H17, w/ final results around mid-2017. We assume a second registration trial may begin by mid-2017, w/ results available around YE17. We now estimate launch in 2019 (was 2018). We reiterate BUY, but are lowering our price target to $23 (was $27) because of launch estimate shift. In our opinion, the stock does not adequately reflect value of CR845 ($60M EV). We acknowledge hypernatremia risk in postsurgical pain, but have a favorable bias toward Phase 3 outcome." (8/7/2016)
Who owns Cara Therapeutics stock?
Cara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Disciplined Growth Investors Inc. MN (3.26%), Chescapmanager LLC (2.51%), Franklin Resources Inc. (2.17%), Opaleye Management Inc. (1.74%), State Street Corp (1.28%) and Allianz Asset Management AG (0.95%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Josef Schoell, Michael E Lewis and Ventures Vi Lp Rho.
Who sold Cara Therapeutics stock? Who is selling Cara Therapeutics stock?
Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Allianz Asset Management AG, GRT Capital Partners L.L.C., Wall Street Associates and Franklin Resources Inc..
Who bought Cara Therapeutics stock? Who is buying Cara Therapeutics stock?
Cara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Disciplined Growth Investors Inc. MN, Chescapmanager LLC, FMR LLC, Dimensional Fund Advisors LP, Russell Investments Group Ltd., Elkfork Partners LLC, State Street Corp and Flinton Capital Management LLC. Company insiders that have bought Cara Therapeutics stock in the last two years include Josef Schoell and Ventures Vi Lp Rho.
How do I buy Cara Therapeutics stock?
Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Cara Therapeutics stock cost?
One share of Cara Therapeutics stock can currently be purchased for approximately $15.03.